Methane

Methane

SCHEMBL667082

C.CC(C)(C)OC(=O)N1CCCC1O

nearest known ligand 0.51

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.45
NPC1 O15118 1/20 0.45
CHRM2 P08172 1/20 0.45
CHRM1 P11229 1/20 0.45
CHRM3 P20309 1/20 0.45
ALDH1A1 P00352 2/20 0.44
HPGD P15428 1/20 0.44
LMNA P02545 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
EPHX1 P07099 1/20 0.42
UCHL1 P09936 1/20 0.41
TSHR P16473 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1550543 0.98 HSD17B10 (0.52) HSD17B10SMN1; SMN2NPC1CHRM2CHRM1
SCHEMBL1115598 0.98 HSD17B10 (0.52) HSD17B10SMN1; SMN2NPC1CHRM2CHRM1
SCHEMBL559852 0.98 HSD17B10 (0.52) HSD17B10SMN1; SMN2NPC1CHRM2CHRM1
SCHEMBL1010839 0.98 HSD17B10 (0.52) HSD17B10SMN1; SMN2NPC1CHRM2CHRM1
Methane SCHEMBL6697096 0.95 HSD17B10 (0.47) HSD17B10SMN1; SMN2NPC1CHRM2CHRM1
SCHEMBL3434909 0.93 HSD17B10 (0.48) HSD17B10SMN1; SMN2NPC1CHRM2CHRM1
SCHEMBL12486284 0.93 HSD17B10 (0.48) HSD17B10SMN1; SMN2NPC1CHRM2CHRM1
SCHEMBL1427524 0.93 HSD17B10 (0.48) HSD17B10SMN1; SMN2NPC1CHRM2CHRM1
SCHEMBL31459726 0.91 HPGD (0.50) HSD17B10SMN1; SMN2NPC1CHRM2CHRM1
SCHEMBL29126181 0.91 HPGD (0.50) HSD17B10SMN1; SMN2NPC1CHRM2CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5922117-A Ink compositions containing alcohols XEROX CORPORATION (US) 1999-07-13 US claimed
US-11681222-B2 Fluorine-containing polymer, purification method, and radiation-sensitive resin composition JSR CORPORATION (JP) 2023-06-20 US disclosed
CN-114890930-A Synthesis method of pyrroltinib intermediate (R, E) -3- (1-methylpyrrolidine-2-yl) acrylic acid hydrochloride 重庆医药高等专科学校 2022-08-12 CN disclosed
US-20220137508-A9 FLUORINE-CONTAINING POLYMER, PURIFICATION METHOD, AND RADIATION-SENSITIVE RESIN COMPOSITION JSR CORPORATION (JP) 2022-05-05 US disclosed
CN-111018767-B Preparation method of D-proline derivative and intermediate thereof 江苏美迪克化学品有限公司 2021-09-28 CN disclosed
US-20210278764-A1 FLUORINE-CONTAINING POLYMER, PURIFICATION METHOD, AND RADIATION-SENSITIVE RESIN COMPOSITION JSR CORPORATION (JP) 2021-09-09 US disclosed
US-11036133-B2 Fluorine-containing polymer, purification method, and radiation-sensitive resin composition JSR CORPORATION (JP) 2021-06-15 US disclosed
US-20200124961-A1 FLUORINE-CONTAINING POLYMER, PURIFICATION METHOD, AND RADIATION-SENSITIVE RESIN COMPOSITION JSR CORPORATION (JP) 2020-04-23 US disclosed
CN-111018767-A Preparation method of D-proline derivative and intermediate thereof 江苏美迪克化学品有限公司 2020-04-17 CN disclosed
US-10620534-B2 Fluorine-containing polymer, purification method, and radiation-sensitive resin composition JSR CORPORATION (JP) 2020-04-14 US disclosed
EP-2131240-A1 POSITIVE-WORKING RADIATION-SENSITIVE COMPOSITION AND METHOD FOR RESIST PATTERN FORMATION USING THE COMPOSITION JSR Corporation (JP) 2009-12-09 EP disclosed
EP-2128706-A1 RESIST PATTERN FORMATION METHOD, AND RESIN COMPOSITION CAPABLE OF INSOLUBILIZING RESIST PATTERN JSR Corporation (JP) 2009-12-02 EP disclosed
US-20090202945-A1 FLUORINE-CONTAINING POLYMER, PURIFICATION METHOD, AND RADIATION-SENSITIVE RESIN COMPOSITION JSR CORPORATION (JP) 2009-08-13 US disclosed
EP-2003148-A9 FLUORINE-CONTAINING POLYMER, PURIFICATION METHOD, AND RADIATION-SENSITIVE RESIN COMPOSITION JSR Corporation (JP) 2009-04-22 EP disclosed
EP-2003148-A2 FLUORINE-CONTAINING POLYMER, PURIFICATION METHOD, AND RADIATION-SENSITIVE RESIN COMPOSITION JSR Corporation (JP) 2008-12-17 EP disclosed
US-20070244128-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS AMIRA PHARMACEUTICALS, INC. (US) 2007-10-18 US disclosed
US-20070065898-A1 Fluorescence polarization assays for binding of caspase inhibitors and probes therefor WYETH (US) 2007-03-22 US disclosed
US-20060234154-A1 Mixture containing acid generator and free radical catalyst; acrylated ester monomer JSR CORPORATION (JP) 2006-10-19 US disclosed
EP-1602975-A1 RADIATION-SENSITIVE RESIN COMPOSITION JSR Corporation (JP) 2005-12-07 EP disclosed
US-5922117-A Ink compositions containing alcohols XEROX CORPORATION (US) 1999-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070244128-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS ALOX5, ALOX15B, ALOX15 HSD17B10 572/4885SMN1; SMN2 4174/4885NPC1 3726/4885
US-20070065898-A1 Fluorescence polarization assays for binding of caspase inhibitors and probes therefor APAF1, CASP1, CASP14 HSD17B10 1758/4885SMN1; SMN2 4769/4885NPC1 865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.